# A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease

> **NCT00087724** · PHASE2 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 510 (—)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** FK962

## Key facts

- **NCT ID:** NCT00087724
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 510 (—)
- **Last updated:** 2012-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087724, "A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00087724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*